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Cardiovascular disease is a frequent complication of which may be important to consider. The percentage of
advancing chronic kidney disease and end-stage renal dis- patients with diabetes in the mild renal insufficiency group
ease (ESRD) [1–4]. A number of investigators have was 1.8 times higher in the men and 2.4 times higher in
shown significant mortality and hospitalization risks as- the women compared to their normal serum creatinine
sociated with the major cardiovascular diseases. Few cohort counterparts. The prevalence of cardiovascular
studies have independently evaluated the associated disease in the mild renal insufficiency group was 29%
mortality and hospitalization risks of the major cardio- higher in men and 119% higher in women compared
vascular diseases within the peritoneal dialysis (PD) and with the normal serum creatinine cohort. The prevalence
hemodialysis (HD) populations. This article reviews the of coronary heart disease was significantly greater in the
existing data in an attempt to assess the impact of isch- mild renal insufficiency group. Congestive heart failure
emic vascular disease and congestive heart failure on was found to be 2.5 times higher in men and 1.7 times
outcomes in PD and HD patients. Since the prevalence higher in women with mild renal insufficiency compared
of these diseases may vary within the different stages to the normal creatinine cohorts. Lastly, evidence of left
of chronic kidney disease, the impact on mortality and ventricular hypertrophy by electrocardiographic criteria
hospitalization also may vary. In order to assess these was 3.2 times higher in men and 4.6 times higher in
risks, the prevalence of cardiovascular disease within women with mild renal insufficiency compared to the
patients with mild-to-moderate kidney dysfunction and normal creatinine group. These findings in this general
those with ESRD are presented along with their associ- population, covering all ages, demonstrates a clear rela-
ated outcomes. tionship between mild-to-moderate renal insufficiency
and a greater burden of all types of cardiovascular dis-
ease, including ischemic heart disease, congestive heartCARDIAC DISEASE IN PATIENTS WITH
failure, and left ventricular hypertrophy [5].MILD-TO-MODERATE RENAL INSUFFICIENCY
Culleton and Wilson also addressed the adjusted riskTwo large studies have quantitated cardiovascular dis-
of death in the normal serum creatinine and mild renalease in the chronic kidney disease population: the Fra-
insufficiency groups. For men, the mild renal insuffi-mingham study by Culleton and Wilson and a Canadian
ciency group had a 30% higher risk of death in the follow-cohort study by Levin et al [5, 6]. In the Culleton and
up period compared to the normal serum creatinineWilson Framingham study, 6223 patients were followed
group. Women had no significant difference in the riskfor up to eleven years, with patients classified as having
of death between the normal serum creatinine and thenormal renal function (N  5707 patients) and 516 pa-
mild renal insufficiency groups. These findings within thetients with mild renal insufficiency. In the group with a
Framingham study group demonstrate that cardiovascu-normal serum creatinine the estimated creatinine clear-
lar disease was more common in the patients with mildance, as determined by the Cockcroft-Gault formula, was
renal insufficiency and the mortality risk in this group88  29 mL/min for men, 68  25 mL/min for women,
was significantly increased in men, but not in women [5].and in the mild renal insufficiency group men had an
A number of investigators also have demonstratedestimated creatinine clearance of 60  18 mL/min and
the relationship between cardiovascular risk factors andwomen 37  11 mL/min. By most current standards, the
outcomes in patients with chronic renal disease. Foleyfemales would be classified as having more severe disease,
et al and Zager et al evaluated the relationship between
blood pressure and risk of death, as well as the relation-
ship between blood pressure and cardiac disease. Foley
et al showed that for every 10 mm Hg rise in mean arterial 2002 by the International Society of Nephrology
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pressure, the risk of developing left ventricular hypertro- be underestimated from the Medical Evidence Form as
reported in the Choice Study, but the trends appear tophy (LVH), LV dilation, ischemic heart disease, or con-
gestive heart failure in the future was between 39% and be consistent [9]. The exact extent of ischemic vascular
disease and congestive heart failure in the dialysis popu-40% higher [3]. Zager et al reported a “U”-shaped func-
tion on the relationship of dialysis blood pressure and lation has been difficult to assess, mainly because of the
differences in data collection methodologies. Whereasthe risk of death [7]. These latter investigators suggested
that the higher risk of death associated with lower blood the chronic kidney disease population has upwards of
30 to 35% of the patients carrying cardiovascular diseasepressure may be secondary to advanced cardiac disease
leading to reduced pump capacity and low blood pres- diagnoses, in the older population (age 67 years and older),
it appears that over 60% of the patients carry a diagnosissures. The risks associated with high blood pressure are
consistent with other findings in the general population of atherosclerotic heart disease, and 60% to 70% of the
patients carry a diagnosis of congestive heart failure be-of ischemic events such as acute myocardial infarction,
cerebral vascular accidents and the development of heart fore they initiate dialysis [8].
The high prevalence of ischemic heart disease in thefailure.
Levin et al also documented the extent of cardiac dialysis population contributes to the significant mortal-
ity risk, particularly after acute myocardial infarction, asdisease in patients with moderate-to-severe kidney dys-
function [6]. They studied 313 patients with chronic kid- reported by Herzog, Ma and Collins [10]. Acute myocar-
dial infarct rates increased by 16% over the last eightney failure, demonstrating that left ventricular mass in-
dex significantly increased with decreasing glomerular years in those patients who survived into their second
year on dialysis. In those dialysis patients who survivedfiltration rates, and left ventricular mass index was highly
associated with falling hemoglobin levels. Additionally, three years, the myocardial infarct rate increased about
7% [8]. New events from cerebrovascular accidents, tran-these investigators showed a 46% prevalence of cardio-
vascular disease within their study population, while 48% sient ischemic attacks, cardiac arrests, major amputations
from peripheral vascular disease, or acute myocardialhad a history of any type of cardiovascular disease, and
infarction also were increased. These data suggest thereapproximately 8% had a history of congestive heart fail-
is a substantial burden of cardiovascular disease, particu-ure. Levin et al’s study demonstrated a higher prevalence
larly in the elderly population on dialysis, but it increasesof disease in patients with more advanced chronic kidney
over time and is associated with increasing event rates.disease than those with less disease noted in the Framing-
Management of patients with cardiac disease is an im-ham study by Culleton and Wilson [6].
portant consideration in assessing the overall outcomes.
Guidelines for clinical practice have suggested that pre-
ISCHEMIC HEART DISEASE AND ventive health care measures including influenza vaccina-
CONGESTIVE HEART FAILURE IN tion, glycemic control monitoring in diabetic patients,
THE ESRD POPULATION and lipid monitoring for patients with ischemic vascu-
Cardiovascular disease present at the time of ESRD lar disease and congestive heart failure should be per-
has been reported by a number of investigators, including formed. Given that these measures are recommended, it
the United States Renal Data System. Information re- is important to determine if providers are assessing their
ported on the Medical Evidence Form 2728, which pro- patients, which was an area recently reported in the 2001
vides documentation of congestive heart failure and isch- USRDS Annual Data Report [8]. There are significant
emic heart disease, shows that HD patients tend to have modality differences between the risk factor monitoring
a greater prevalence of these conditions than their PD of the dialysis population. For example, HD patients are
counterparts. The distribution of cardiac comorbidity at more likely to receive influenza vaccinations than perito-
the initiation of dialysis appears to be greatest in the neal dialysis patients, particularly in the age group under
northeastern portion of the United States, including the 65 years old [8]. The likelihood of hospitalizations in the
industrial northeast, Indiana, Illinois, Wisconsin, and HD population after influenza vaccination appears to be
Minnesota [8]. Therefore, comorbidity is not only com- heavily influenced by diabetic status and gender. Female
mon within the ESRD program, but is more heavily diabetics who receive influenza vaccinations are less likely
concentrated in the industrial northeast compared to the to be hospitalized for influenza, pneumonia, and vascular
rest of the country. Given the high degree of comorbidity access infections compared to their male counterparts
and its geographic distribution in the country, the man- or those patients who are not diabetic. This is only one
agement of the ischemic heart disease risk factors may example of how preventive health care measures may
significantly influence overall patient care and outcomes, impact overall patient outcomes.
particularly depending on which area of the country is Other cardiovascular risk factor tests include glycemic
considered. control monitoring for microvascular disease in the dia-
betic population and lipid monitoring for ischemic vascu-The actual prevalence of comorbidity, however, may
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lar disease. The utilization of these tests also varies by blacks as well as diabetic and non-diabetic patients who
survived nine months of dialysis treatment [8]. The entrydialysis modality. The percent of diabetic patients receiv-
ing glycemic control monitoring has improved from 1996 period was used to characterize the comorbidity, severity
of disease, hemoglobin levels and dialysis therapy fromto 1999; however, up to 50% of the diabetic patients still
do not have a single glycosylated hemoglobin test per- month 4 to month 9 of dialysis therapy. In the HD pop-
ulation, among the cardiovascular risk factors, conges-formed within a year of survival. The variation in utiliza-
tion of glycosylated hemoglobin monitoring is significant tive heart failure was associated with a 45% greater risk
of death in the white population, a 21% increased risk ofacross the country, with almost a twofold difference be-
tween the health services areas with the lowest utilization death within the black population, a 51% increased risk
of death in the non-diabetics, and a 24% increased risk ofcompared to the areas with the highest monitoring rates
[8]. Lipid monitoring for macrovascular disease varies al- death in the diabetic population. The second leading car-
diovascular risk factor associated with death was othermost 50% between health services areas in the United
States in the diabetic population and almost 40% in the cardiac disease, consisting of arrhythmic disorders and val-
vular heart disease. Additional cardiovascular risk fac-non-diabetic population. These data suggest that even
though preventive measure monitoring has been recom- tors included a history of cerebrovascular accidents
(CVAs) and transient ischemic attacks (TIAs) withinmended to reduce the burden of cardiovascular disease,
they are in fact markedly underutilized in the dialysis pop- the black population that was associated with a 30%
increase in subsequent death. In the white population,ulation, which may contribute to the adverse outcomes.
the relative risk of CVAs/TIAs was only 8%. Studies by
Held et al also evaluated the risk of cardiac complication
TREATMENT OF ISCHEMIC HEART DISEASE in the PD and HD populations [11]. Congestive heart
The previous section described that cardiovascular failure incurred a 30% greater risk of death in the dia-
and diabetic risk factor monitoring appears to be under- betic population and a 23% greater risk in the non-
utilized in the dialysis population. If risk factor monitor- diabetic populations across PD and HD therapy. The
ing is underutilized, then other interventions to treat interaction of cardiovascular risks in the PD and HD
ischemic heart disease may also be limited, which may populations has rarely been assessed. In the Held et
help explain the poor survival of dialysis patients. These al study no interaction terms between cardiovascular
concerns may be well founded in that there appears to disease and the individual dialysis therapies were per-
be underutilization of diagnostic and therapeutic inter- formed, leaving this area unanswered.
ventions for those individuals at the greatest risk for
ischemic cardiovascular events. Stress test, coronary an-
CARDIOVASCULAR RISK FACTORS ANDgiography, and revascularization procedures are only
THE IMPACT ON HOSPITALIZATIONSperformed in a minority of patients within 30 days after
IN DIALYSIS PATIENTSan acute myocardial infarct [8]. Approximately 30% of
the patients who survived an acute myocardial infarct Cardiovascular risk factors also are strong predictors
of hospitalizations in both PD and HD populations. Thewere ever tested or received revascularization proce-
dures, with only 5% being tested within the first 30 days recent USRDS 2001 Annual Data Report showed that
congestive heart failure in the white population incurredand the remaining 25% being tested after a 30-day sur-
vival period. In those individuals who had acute myocar- a 16% greater risk of hospitalization, while within the
black population this was only 8% [8]. Ischemic heartdial infarction, less than 20% of the patients ever received
a revascularization procedure, whether the patient sur- disease incurred a 13% greater risk in the white popula-
tion, while in the black population it was also only 8%.vived less than 30 days or longer than 30 days. These data
suggest that diagnostic procedures and interventions for A past history of hospitalizations in all populations was
highly predictive of the subsequent likelihood of hospi-ischemic heart disease are underutilized in the dialysis
population and may reflect a strong bias toward thera- talizations in the future, as well as the likelihood of death.
Therefore, ischemic heart disease and congestive heartpeutic nihilism.
failure are major sources of morbidity and mortality in
dialysis patients in general, with subtle differences be-
CARDIOVASCULAR RISK FACTORS tween PD and HD populations.
AND THE IMPACT ON SURVIVAL OF
DIALYSIS PATIENTS
OTHER AREAS OF MORBIDITY WITHINThe USRDS and a number of investigators have evalu-
THE PD AND HD POPULATIONSated risk factors for survival of dialysis patients. The
most recent data reported in the USRDS 2001 Annual The major source of morbidity in the dialysis popula-
tion is secondary to hospitalizations. The pattern of hos-Data Report evaluated the risk of death in whites and
Collins: CHF and patient outcomeS-6
pitalizations, however, between the two modalities is quite and other comorbidities needs to be defined as well as
the associations with other comorbid conditions such asdifferent. When assessing period-prevalent patients over
the years 1991 through 1999, HD patients have higher advancing anemia. The loss of ultrafiltration capacity
over time in the PD population secondary to the develop-hospitalization rates within the first year post-ESRD
compared to PD patients. However, by the second year ment high transport characteristics is receiving increased
attention, since fluid overload and heart failure are im-of renal replacement therapy, PD patient have a 20%
higher hospitalization rate than the HD population. This portant complications in this population. New PD solu-
tions, which are described further in this Supplement,pattern also is present in the prevalent patients who have
been on dialysis for two to three years. These trends in particularly those with icodextrin, may provide an oppor-
tunity to improve the management of fluid overload andhospitalization rates over time may be particularly im-
portant for PD patients, since concerns have been raised congestive heart failure in the PD population [26–29].
Other interventions, however, also should be addressed.over the loss of ultrafiltration with subsequent difficulties
with fluid management [12–16]. This may be of particular For example, the PD population receiving erythropoietin
treatment has lower hemoglobin levels (see Figures 4.5,importance in the older population, since recent studies
on the elderly in the United States have shown that PD 4.6, and 4.7 of the USRDS 2001 Annual Data Report
[30]) than the HD population receiving erythropoietinpatients are associated with an increased risk of death
compared to their HD counterparts [17]. Since the older (EPO). The comparable hemoglobin levels in PD and
HD population at 11.6 g/dL and 11.7 g/dL reported by thepopulation has a greater prevalence of ischemic heart
disease and congestive heart failure, these associations Clinical Performance Measures project under represents
the true under treatment of anemia [8, 30]. The lowermay be important to consider and may be amenable to
improvements in the management of fluid overload and hemoglobin values noted in the erythropoietin-treated
patients suggest that the non-erythropoietin–treated PDultrafiltration failure in the PD population [17].
Treatment of congestive heart failure in the dialysis and HD patients have higher hemoglobin values. An
assessment of cardiovascular and congestive heart failurepopulation may need to be improved in the HD popu-
outcomes in PD patients with higher hemoglobin valueslation as well. The concerns over increased death rates
should be undertaken.over the long weekend inter-dialytic interval may be sec-
The remainder of this Supplement concentrates onondary to fluid overload and congestive heart failure
newer interventions for dialytic therapy in the PD popu-[18]. The intermittent nature of HD also should be given
lation, which may address these areas of cardiovascularmore consideration since daily dialysis may provide a
disease and concerns relative to the impact of congestivemore effective alternative [19–21]. An equally important
heart failure as a risk factor in the PD population.consideration is the medical management of heart failure
as recommended in accepted practice guidelines. The
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